Spyre Therapeutics Announces Commencement of Public Offering of Common Stock

Key Facts

1Spyre Therapeutics announced the commencement of an underwritten public offering of its common stock.

2The company expects to grant underwriters a 30-day option to purchase an additional 15% of the shares offered.

Spyre Therapeutics announced the commencement of an underwritten public offering of its common stock. According to a statement reported by GlobeNewswire, the company expects to grant underwriters a 30-day option to purchase an additional 15% of the shares offered in the transaction.

This capital raise follows a session where SYRE shares closed at $93.19 on October 2, 2026. During that trading day, the stock reached a high of $95.27 and a low of $90.48, as the clinical-stage biotech firm moves to secure funding for the development of its immunology therapies.